Company intelligence / Profile preview

Neograft Technologies

Taunton, Massachusetts, United Statesbloomberg.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Neograft Technologies developed the Angioshield System, a catheter-based medical device designed to reinforce and protect saphenous vein grafts during coronary artery bypass surgery. The system creates a micro-fibrous polymer sleeve around harvested veins to prevent overdilation and improve long-term patency. Two clinical trials were conducted demonstrating feasibility and safety for use in CABG procedures; however, there are no recent updates indicating further development or commercialization.

Therapeutic areas: Cardiovascular
Modalities: DevicePolymer-based vascular support device
Industry: Surgical Medical Devices

Drug pipeline

1 asset

Angioshield

Pre-clinical

Indications: Coronary artery disease

Beyond the preview

Go deeper on Neograft Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neograft Technologies.

Explore the full profile